This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0003319708321106v1 59/2_suppl/65S    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Laaksonen, R. Articles by Oreic, M. Search for Related Content PubMed PubMed Citation Articles by Laaksonen, R. Articles by Oreic, M. Pubmed/NCBI databases Medline Plus Health Information Muscle Disorders Statins Social Bookmarking                         What's this?

Lipidomics-Based Safety Biomarkers for Lipid-Lowering Treatments

Reijo Laaksonen, MD, PhD^*, Minna T. Jänis, PhD, and Matej Oreic, PhD

Zora Biosciences Oy

^* To whom correspondence should be addressed. E-mail: reijo.laaksonen{at}zora.fi.

	Abstract

Recent data suggest that aggressive lipid-lowering treatment results in significant reductions of atherosclerotic complications, ie, strokes, heart attacks, or peripheral vascular diseases. Thus, more patients will be titrated to higher doses of statins in order to reach the aggressive targets of low-density lipoprotein– cholesterol reduction. However, aggressive treatment with high statin doses has increased the risk of statininduced myopathy. The incidence of myopathy in cohort studies and in randomized trials has been low, supporting the good safety profile of statin drugs. However, muscle effects seem to be more frequent in clinical practice. Of all statin users, approximately 1% to 5% suffers from muscular symptoms caused by medication. This potentially reduces the compliance toward treatment and number of patients reaching their treatment targets due to withdrawal of therapy. Thus, novel biomarkers are needed for prediction or improved diagnoses of statin-induced side effects. This would potentially increase the quality of life of patients and improve treatment results. Using lipidomic analysis, we found that the plasma lipidomic changes following simvastatin treatment correlate with the muscle expression of the arachidonate 5-lipoxygenase-activating protein. Intriguingly, these results suggest that the plasma lipidomic profile may serve as a highly sensitive biomarker of statin-induced metabolic alterations in muscle and may thus allow us to identify patients who should be treated with a lower dose to prevent a possible toxicity.

First published on July 16, 2008, doi:10.1177/0003319708321106

Angiology 2008;59:65S.

A more recent version of this article appeared on August 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?